Unreported formal assessment of unblinding occurred in 4 of 10 randomized clinical trials, unreported loss of blinding in 1 of 10 trials

Journal of Clinical Epidemiology

Volumn 81, Issue , 2017, Pages 42-50

  Bello, Segun ^a,b   Moustgaard, Helene ^a   Hróbjartsson, Asbjørn ^a,c  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF IBADAN   (Nigeria)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Blinding; Designs; Masking; Methods; Randomized clinical trials; Reporting; Unblinding

Indexed keywords

ARTICLE; FOLLOW UP; HEALTH CARE PERSONNEL; PRIORITY JOURNAL; PUBLICATION; QUESTIONNAIRE; RANDOM SAMPLE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SENSITIVITY ANALYSIS; STUDY DESIGN; EPIDEMIOLOGY; HUMAN; PROCEDURES; RISK; STATISTICAL BIAS; STATISTICS AND NUMERICAL DATA;

BIAS (EPIDEMIOLOGY); EPIDEMIOLOGIC RESEARCH DESIGN; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SURVEYS AND QUESTIONNAIRES;

EID: 84994834787     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2016.08.002     Document Type: Article

References (31)

1. [1] Savović, J., Jones, H.E., Altman, D.G., Harris, R.J., Jüni, P., Pildal, J., et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 157 (2012), 429–438.
2. [2] Hróbjartsson, A., Thomsen, A.S.S., Emanuelsson, F., Tendal, B., Hilden, J., Boutron, I., et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ, 344, 2012, e1119.
3. [3] Hróbjartsson, A., Thomsen, A.S.S., Emanuelsson, F., Tendal, B., Hilden, J., Boutron, I., et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. CMAJ 185 (2013), E201–E211.
4. [4] Hróbjartsson, A., Thomsen, A.S.S., Emanuelsson, F., Tendal, B., Rasmussen, J.V., Hilden, J., et al. Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. Int J Epidemiol 43 (2014), 937–948.
5. [5] Schulz, K.F., Chalmers, I., Altman, D.G., The landscape and lexicon of blinding in randomised trials. Ann Intern Med 136 (2002), 254–259.
6. [6] Hróbjartsson, A., Boutron, I., Blinding in randomized clinical trials: imposed impartiality. Clin Pharmacol Ther 90 (2011), 732–736.
7. [7] Hróbjartsson, A., Emanuelsson, F., Thomsen, A.S.S., Hilden, J., Brorson, S., Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. Int J Epidemiol 43:4 (2014), 1272–1283.
8. [8] Eby, G.A., Davis, D.R., Halcomb, W.W., Reduction in duration of common cold by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother 25 (1984), 20–24.
9. [9] Farr, B.M., Gwaltney, J.M. Jr., The problem of taste in placebo matching: an evaluation of zinc gluconate for the common cold. J Chron Dis 40:9 (1987), 875–879.
10. [10] Fai, C.K., Qi, G.D., Wei, D.A., Chung, L.P., Placebo preparation for the proper clinical trials of herbal medicine—requirements, verification and quality control. Recent Pat Inflamm Allergy Drug Discov 5 (2011), 169–174.
11. [11] Byington, R.P., Curb, J.D., Mattson, M.E., Assessment of double-blindness at the conclusion of the beta-Blocker Heart Attack Trial. JAMA 253 (1985), 1733–1736.
12. [12] Colbert, A.P., Markor, M.S., Carlson, N., Gregory, W.L., Carlson, H., Elmer, P.J., Static magnetic field therapy for carpal tunnel syndrome: a feasibility study. Arch Phys Med Rehabil 91 (2010), 1098–1104.
13. [13] Brent, D., Emslie, G., Clark, G., Wagner, K.D., Asarnow, J.R., Keller, M., et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioural therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 299 (2008), 901–913.
14. [14] Montori, V.M., Bhandari, M., Devereaux, P.J., Manns, B.J., Ghali, W.A., Guyatt, G.H., In the dark. The reporting of blinding status in randomised controlled trials. J Clin Epidemiol 55 (2002), 787–790.
15. [15] Haahr, M.T., Hróbjartsson, A., Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. Clin Trials 3 (2006), 360–365.
16. [16] Bello, S., Moustgaard, H., Hróbjartsson, A., The risk of unblinding was infrequently and incompletely reported in 300 randomised clinical trial publications. J Clin Epidemiol 67 (2014), 1059–1069.
17. [17] Hróbjartsson, A., Forfang, E., Haahr, M.T., Als-nielsen, B., Brorson, S., Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. Int J Epidemiol 36 (2007), 654–663.
18. [18] Sacket, D.L., Turning a blind eye: why we don't test for blindness at the end of our trial. BMJ, 328, 2004, 1136.
19. [19] Altman, D.G., Schulz, K.F., Moher, D., Turning a blind eye: testing the success of blinding and the CONSORT statement. BMJ, 328, 2004, 1135.
20. [20] Asch, D.A., Jedrziewski, M.K., Christakis, N.A., Response rates to mail surveys published in medical journals. J Clin Epidemiol 50 (1997), 1129–1136.
21. [21] Devereaux, P.J., Choi, P.T., El-Dika, S., Bhandari, M., Montori, V.M., Schünemann, H.J., et al. An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods. J Clin Epidemiol 57 (2004), 1232–1236.
22. [22] Hill, C.L., LaValley, M.P., Felson, D.T., Discrepancy between published report and actual conduct of randomized clinical trials. J Clin Epidemiol 55 (2002), 783–786.
23. [23] Shipton, D., Tappin, D.M., Vadiveloo, T., Crossley, J.A., Aitken, D.A., Chalmers, J., Reliability of self reported smoking status by pregnant women for estimating smoking prevalence: a retrospective, cross sectional study. BMJ, 339, 2009, b4347.
24. [24] Chan, A.W., Hróbjartsson, A., Haahr, M.T., Gøtzsche, P.C., Altman, D.G., Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published trials. JAMA 291 (2004), 2457–2465.
25. [25] Hopewell, S., Dutton, S., Yu, L.M., Chan, A.W., Altman, D.G., The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ, 340, 2010, c723.
26. [26] Chan, A.W., Altman, D.G., Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 365 (2005), 1159–1162.
27. [27] Glasziou, P., Meats, E., Heneghan, C., Shepperd, S., What is missing from descriptions of treatments in trials and reviews?. BMJ 336 (2008), 1472–1474.
28. [28] Bello, S., Wei, M., Hróbjartsson, A., The matching quality of experimental and control interventions in blinded pharmacological randomised clinical trials: a methodological systematic review. BMC Med Res Methodol, 16, 2016, 18.
29. [29] Moher, D., Hopewell, S., Schulz, K.F., Montori, V., Gøtzsche, P.C., Devereaux, P.J., et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ, 340, 2010, c869.
30. [30] World Health Organization. Good manufacturing practices for pharmaceutical products: main principles. WHO Tech Rep Ser 2003; No. 908(Annex 4): 36–89.
31. [31] Chan, A., Tetzlaff, J.M., Gøtzsche, P.C., Altman, D.G., Mann, H., Berlin, J.A., et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ, 346, 2013, e7586.